Adenovirus-based genetic vaccines for biodefense

Julie L. Boyer, Gary Kobinger, James M. Wilson, Ronald Crystal

Research output: Contribution to journalReview article

42 Citations (Scopus)

Abstract

The robust host responses elicited against transgenes encoded by E1 -E3- adenovirus (Ad) gene transfer vectors can be used to develop Ad-based vectors as platform technologies for vaccines against potential bioterror pathogens. This review focuses on pathogens of major concern as bioterror agents and why Ad vectors are ideal as anti-bioterror vaccine platforms, providing examples from our laboratories of using Ad vectors as vaccines against potential bioterror pathogens and how Ad vectors can be developed to enhance vaccine efficacy in the bioterror war.

Original languageEnglish
Pages (from-to)157-168
Number of pages12
JournalHuman Gene Therapy
Volume16
Issue number2
DOIs
Publication statusPublished - 1 Feb 2005
Externally publishedYes

Fingerprint

Adenoviridae
Vaccines
Transgenes
Technology
Genes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Adenovirus-based genetic vaccines for biodefense. / Boyer, Julie L.; Kobinger, Gary; Wilson, James M.; Crystal, Ronald.

In: Human Gene Therapy, Vol. 16, No. 2, 01.02.2005, p. 157-168.

Research output: Contribution to journalReview article

Boyer, Julie L. ; Kobinger, Gary ; Wilson, James M. ; Crystal, Ronald. / Adenovirus-based genetic vaccines for biodefense. In: Human Gene Therapy. 2005 ; Vol. 16, No. 2. pp. 157-168.
@article{a1aa7c928fb24df281cffb0ff15dea79,
title = "Adenovirus-based genetic vaccines for biodefense",
abstract = "The robust host responses elicited against transgenes encoded by E1 -E3- adenovirus (Ad) gene transfer vectors can be used to develop Ad-based vectors as platform technologies for vaccines against potential bioterror pathogens. This review focuses on pathogens of major concern as bioterror agents and why Ad vectors are ideal as anti-bioterror vaccine platforms, providing examples from our laboratories of using Ad vectors as vaccines against potential bioterror pathogens and how Ad vectors can be developed to enhance vaccine efficacy in the bioterror war.",
author = "Boyer, {Julie L.} and Gary Kobinger and Wilson, {James M.} and Ronald Crystal",
year = "2005",
month = "2",
day = "1",
doi = "10.1089/hum.2005.16.157",
language = "English",
volume = "16",
pages = "157--168",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Adenovirus-based genetic vaccines for biodefense

AU - Boyer, Julie L.

AU - Kobinger, Gary

AU - Wilson, James M.

AU - Crystal, Ronald

PY - 2005/2/1

Y1 - 2005/2/1

N2 - The robust host responses elicited against transgenes encoded by E1 -E3- adenovirus (Ad) gene transfer vectors can be used to develop Ad-based vectors as platform technologies for vaccines against potential bioterror pathogens. This review focuses on pathogens of major concern as bioterror agents and why Ad vectors are ideal as anti-bioterror vaccine platforms, providing examples from our laboratories of using Ad vectors as vaccines against potential bioterror pathogens and how Ad vectors can be developed to enhance vaccine efficacy in the bioterror war.

AB - The robust host responses elicited against transgenes encoded by E1 -E3- adenovirus (Ad) gene transfer vectors can be used to develop Ad-based vectors as platform technologies for vaccines against potential bioterror pathogens. This review focuses on pathogens of major concern as bioterror agents and why Ad vectors are ideal as anti-bioterror vaccine platforms, providing examples from our laboratories of using Ad vectors as vaccines against potential bioterror pathogens and how Ad vectors can be developed to enhance vaccine efficacy in the bioterror war.

UR - http://www.scopus.com/inward/record.url?scp=14844303332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844303332&partnerID=8YFLogxK

U2 - 10.1089/hum.2005.16.157

DO - 10.1089/hum.2005.16.157

M3 - Review article

C2 - 15761256

AN - SCOPUS:14844303332

VL - 16

SP - 157

EP - 168

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 2

ER -